Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Oct 4:4:22.
doi: 10.1186/1476-511X-4-22.

The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats

Fawzia M Refaie  1 , Amr Y Esmat, Soad M Abdel Gawad, Aida M Ibrahim, Mona A Mohamed
Affiliations

The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats

Fawzia M Refaie et al. Lipids Health Dis. .

Abstract

In the present study, the effects of subchronic treatments (4 weeks) of hypercholesterolemic (single) and diabetic-hypercholesterolemic (combined) rats with 4 (3H) quinazolinone and 2 halogenated derivatives (6, 8-dibromo-2-methy-4 (3H) quinazolinone and 6-iodo-2-methyl-4(3H) quinazolinone) at a sublethal dose level (2 mg/Kg) on cholesterol metabolism were investigated. Bezafibrate, a hypolipidemic drug was used as a reference compound for data comparison. Treatment of rats with single and combined hypercholesterolemia with quinazolinone compounds gave rise to highly significant reductions in serum total cholesterol and cholesterol ester levels, whereas serum triacylglycerol level was significantly reduced only after treatment with halogen-substituted quinazolinones in single hyper-cholesterolemia, compared to the control group. The effects of different quinazolinones and bezafibrate on reduction of serum LDL-C level were comparable in single hypercholesterolemia but significantly different in combined hypercholesterolemia. Results obtained from this study suggest that the antihyperlipidemic effect of quinazolinone compounds was brought about by inhibition of dietary cholesterol absorption and / or intestinal ACAT activity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in the percentage of body weight gain in hypercholesterolemic rats treated with the different modalities throughout the experimental period. *denotes statistical significance (p < 0.05) at the 4th week point compared to normal controls.
Figure 2
Figure 2
Changes in the percentage of body weight gain in diabetic-hypercholesterolemic rats treated with the different modalities throughout the experimental period. *denotes statistical significance (p < 0.05) at the 4th week point compared to normal controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Habib NS, Ismail KA, El-Tombary AA, Abd El-Aziem T. Antilipidemic agents, Part IV: Synthesis and antilipidemic testing of some heterocyclic derivatives of hexadecyl and cyclohexyl hemisuccinate esters. Pharmazie. 2000;55:495–499. - PubMed
    1. Fuster V, Alexander PW, O'Rourke RA, Roberts R, King SB, Wellens HJ. Hurst's the heart. 10. Vol. 3. New York, Mc Graw-Hill; 2001. Atherogenesis and its determinants; p. 1065.
    1. Devlin T. Textbook of biochemistry with clinical correlations. 3. New York, Wiley-Liss Inc; 1995. pp. 376–381.
    1. McNamara DJ. Dietary cholesterol and atherosclerosis. Biochim Biophys Acta. 2000;1529:310–320. - PubMed
    1. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:19–27. doi: 10.1046/j.1462-8902.2003.0310.x. - DOI - PubMed